Serum Metabolic Characteristics and Biomarkers of Early-Stage Heart Failure

Abstract

Aim: We aimed to identify metabolic characteristics of early-stage heart failure (HF) and related biomarkers. Patients & methods: One hundred and forty-three patients with New York Heart Association class I–IV HF and 34 healthy controls were recruited. Serum metabolic characteristics of class I HF were analyzed and compared with those of class II–IV HF. Potential biomarkers of class I HF with normal N-terminal-pro-B-type natriuretic peptide (NT-proBNP) level were screened and validated in additional 72 subjects (46 class I patients and 26 controls). Results & conclusion: Eleven metabolites were found disturbed in class I HF, and five of which were also disturbed in class II–IV HF. Glutamine and tyrosine showed high value to identify class I HF with normal NT-proBNP level. The diagnostic potential of glutamine was partially confirmed in the validate set, holding a promise to detect early HF with normal NT-proBNP level.

Serum Metabolic Profiling Identifies Key Differences between Patients with Single-Ventricle Heart Disease and Healthy Controls

“…There is a significant and growing body of literature where metabolomic analyses have been performed in adult HF subjects [27][28][29][30]. To our knowledge, there exist only two reports of metabolomic analyses of the myocardium of SV subjects, including one in adult non-failing SV patients with a systemic LV [18,19] and one in young SVNF and SVHF patients with a systemic RV [20].…”

Association between methionine sulfoxide and risk of moyamoya disease

“…In recent years, with the further study of multi-omics technologies, researchers have found that the ultimate effect of gene or protein regulatory action was to cause changes in metabolites in body ( Holmes et al, 2018 ; Yang et al, 2018 ; Zhang et al, 2022 ). Metabolomics studied endogenous small molecule compounds at the end of metabolic pathways, which could skip the complex regulatory processes of body and directly reflect the final physiological and pathological changes ( Ke et al, 2018 ; Guo et al, 2020 ; Chumachenko et al, 2022 ). Through the analysis of differential metabolites, researchers could reveal pathogenic mechanisms, confirm diagnostic biomarkers, estimate disease risk, and monitor treatment processes ( Wishart, 2019 ; Shin et al, 2020 ; Wang et al, 2020 ).…”